- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.10. | 4 reasons why life sciences still fail women at the top, despite a female-majority workforce: report | ||
| 03.10. | Rocket aborts mission to get gene therapy approved by FDA for rare bone marrow disorder | ||
| 02.10. | After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks | ||
| 02.10. | Singapore drug discovery platform heads to Nasdaq via SPAC deal | ||
| 02.10. | Bolt halves workforce (again) to find cash to fund immunotherapy readout | ||
| 01.10. | Takeda taps out of cell therapy arena as part of strategic shift | ||
| 01.10. | FDA snubs Cyprium-Sentynl drug for rare pediatric disease due to manufacturing issues | ||
| 01.10. | Amid funding cuts, White House pledges $100M to pediatric cancer data initiative | ||
| 01.10. | Irish biotech launches with $21M to shuttle RNAi meds to brain | ||
| 01.10. | BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future | ||
| 01.10. | Kyorin pens $105M pact for Japan rights to Hinge's preclinical lupus drug | ||
| 30.09. | Novo dumps cell therapy partner Heartseed, calling off $598M collab amid restructuring | ||
| 30.09. | Barinthus Bio joins forces with metabolic disease biotech in reverse merger | ||
| 30.09. | AnaptysBio plans to split biotech and Jemperli royalties into separate businesses | ||
| 30.09. | Opus sets sights on FDA talks after posting pediatric gene therapy data | ||
| 30.09. | Pfizer's new prize Metsera touts 14% weight loss, 'class-leading tolerability' for lead GLP-1 drug | ||
| 30.09. | Sutro loses 3rd of workforce in ADC biotech's 2nd round of layoffs this year | ||
| 29.09. | HHS division refers Harvard for potential debarment as funding clash takes new form | ||
| 29.09. | BioLineRx forges partnership with Norwegian biotech to advance cancer candidate | ||
| 29.09. | After surprise trial listing, Applied Tx still doesn't have any updates on its rare disease asset | ||
| 29.09. | Gilead pumps up virology pipeline with drug transporter deal | ||
| 29.09. | IO lays off 50% of employees after FDA derails cancer vaccine approval plan | ||
| 29.09. | Enanta sees RSV drug fail phase 2b but finds positives in secondaries and subgroup | ||
| 29.09. | MoonLake's stock crashes after high placebo rate eclipses IL-17 drug's phase 3 readouts | ||
| 29.09. | Genmab pays $8B to buy Merus and its phase 3 bispecific that wowed analysts |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .